Insmed Incorporated (INSM) Stock
Fundamentals
Latest news
About Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. William H. Lewis J.D., M.B.A. | President, CEO & Chairman | 1969 |
| Ms. Sara M. Bonstein M.B.A. | Chief Financial Officer | 1981 |
| Mr. Roger Adsett M.B.A. | Chief Operating Officer | 1969 |
| Mr. Michael Alexander Smith J.D. | Chief Legal Officer & Corporate Secretary | 1978 |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer | 1964 |
| Mr. Brian K. Kaspar Ph.D. | Chief Scientific Officer | 1974 |
| Bryan Dunn | Vice President of Investor Relations | — |
| Ms. Christie Camelio | Chief Compliance Officer | — |
| Ms. Claire Mulhearn | Vice President of Corporate Communications | — |
| Ms. S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer | 1968 |



